Teva Pharmaceutical Industries Ltd (NYSE:TEVA)’s share price was up 0.5% on Monday . The company traded as high as $10.28 and last traded at $10.25, approximately 13,467,456 shares were traded during mid-day trading. A decline of 47% from the average daily volume of 25,398,352 shares. The stock had previously closed at $10.20.
A number of research analysts recently weighed in on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $8.00 target price on the stock in a report on Tuesday, November 12th. Gabelli upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, October 16th. Raymond James reduced their target price on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Wells Fargo & Co reduced their target price on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating on the stock in a report on Monday, September 30th. Finally, Royal Bank of Canada reiterated a “hold” rating and issued a $10.00 target price on shares of Teva Pharmaceutical Industries in a report on Thursday, August 8th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $10.83.
The firm has a market capitalization of $10.23 billion, a PE ratio of 3.69, a price-to-earnings-growth ratio of 1.00 and a beta of 1.73. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56. The stock has a 50-day moving average price of $7.79 and a 200-day moving average price of $8.74.
Several hedge funds and other institutional investors have recently modified their holdings of the company. First Interstate Bank bought a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $28,000. Pacer Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at $32,000. AdvisorNet Financial Inc increased its holdings in shares of Teva Pharmaceutical Industries by 71.3% in the third quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after buying an additional 1,525 shares in the last quarter. Kavar Capital Partners LLC bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at $35,000. Finally, Motco bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at $28,000. Institutional investors and hedge funds own 57.81% of the company’s stock.
Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: Convertible Shares
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.